[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351417-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351417-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","evaluating-the-impact-of-putative-metformin-targets-on-cancer-outcomes-a-drug-target-mendelian-randomization-study","Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes - A Drug-Target Mendelian Randomization Study","","Genetic evidence is used to validate metformin repositioning for cancer prevention, addressing inconsistent findings from observational studies. The study applied drug-target Mendelian randomization to estimate genetically proxied effects of 11 putative metformin targets on five major cancers. Instrument validity and multiple-comparison control were assessed with sensitivity analyses, including conventional MR using HbA1c inverse-variance methods. Findings indicate PRKAG1, but not GPD1, is linked to reduced colorectal cancer risk.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/evaluating-the-impact-of-putative-metformin-targets-on-cancer-outcomes-a-drug-target-mendelian-randomization-study/351417/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/evaluating-the-impact-of-putative-metformin-targets-on-cancer-outcomes-a-drug-target-mendelian-randomization-study/351417.png","ImageObject",300,407,{"name":42,"@type":43},"Riley West","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the goal of this study?","Question",{"text":63,"@type":64},"To genetically assess whether putative metformin targets have causal effects on cancer outcomes, supporting genetic validation for metformin repositioning in cancer prevention.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the metformin targets evaluated?",{"text":68,"@type":64},"Genetic proxies were created for 11 metformin targets based on tissue-specific gene expression, HbA1c, and type 2 diabetes associations, then tested against five major cancers using drug-target Mendelian randomization.",{"name":70,"@type":61,"acceptedAnswer":71},"Which target showed an association with cancer risk?",{"text":72,"@type":64},"PRKAG1 (AMPKγ1) showed reduced risk of colorectal cancer, while GPD1 showed no significant association.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351417,1790178632,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099523885074,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Diabetes, Obesity and Metabolism   \n ORIGINAL ARTICLE  OPEN ACCESS   \nEvaluating the Impact of Putative Metformin Targetson Cancer Outcomes: A Drug-Target Mendelian Randomization Study  \nXingyu Shen1 | Shan Luo1,2  | Jie Zheng3,4,5 | Celine Sze Ling Chui6 | Ian Chi Kei Wong7,8,9,10 | Eric Yuk Fai Wan2,8,11,12  | Catherine Mary Schooling1,13 | Shiu Lun Au Yeung1   \n1School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong (Special Administrative Region), China | 2Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong (Special Administrative Region),  \nChina | 3Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China | 4Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Shanghai Digital Medicine Innovation Center, Ruijin Hospital. Shanghai Jiao Tong University School of Medicine, Shanghai, China | 5MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Bristol, UK | 6School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong (Special Administrative Region), China | 7Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong (Special Administrative Region), China | 8Aston Pharmacy School, Aston University, Birmingham, UK | 9School of Pharmacy, Medical Sciences Division, Macau University of Science and Technology, Macau (Special Administrative Region), China | 10Advanced Data Analytics for Medical Science Limited, Hong Kong (Special Administrative Region), China | 11The Institute of Cardiovascular Science and Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong (Special Administrative Region), China | 12Comprehensive Primary Healthcare Collaboratory, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong (Special  \nAdministrative Region), China | 13Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA Correspondence: Shan Luo (aprilluo@hku.hk)  \nReceived: 15 December 2025 | Revised: 9 February 2026 | Accepted: 15 February 2026  \nKeywords: cancer | genome-wide association study (GWAS) | Mendelian randomization | metformin | reposition  \nABSTRACT  \nAims: Observational studies show metformin use associated with lower cancer risk, although experimental evidence is inconsistent. To provide genetic validation for repositioning of metformin in cancer prevention, we assessed genetically proxied effects of putative metformin targets on cancer outcomes using a drug-target Mendelian randomization (MR) design.  \nMaterials and Methods: We identified genetic proxies of 11 metformin targets (PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, ETFDH, GPD1, SLC47A1 and ACACB) based on their associations with tissue-specific gene expression, overall/sex-specific HbA1c and type 2 diabetes. We then evaluated genetically proxied effects of these targets on five major cancers using MR. We also employed a conventional MR design to assess the relationship of HbA1c with cancer using the inverse variance method, with sensitivity analyses. Associations were corrected for multiple comparisons using false discovery rates. Results: We identified two genetic proxies of putative metformin targets (PRKAG1 and GPD1) as valid instrumental variables (F statistics > 10). PRKAG1 was associated with a reduced risk of colorectal cancer (OR: 0.74 per mmol/mol reduction in overall HbA1c, 95% CI: 0.63–0.87; p = 0.001), with consistent findings in sex-specific analysis. This effect was unlikely mediated by HbA1c ","cbCaifPuGcGrMtHA","https://ap.wps.com/l/cbCaifPuGcGrMtHA","pdf",1428087,"English","# Abstract\n## Aims\n## Materials and Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the goal of this study?\",\"answer\":\"To genetically assess whether putative metformin targets have causal effects on cancer outcomes, supporting genetic validation for metformin repositioning in cancer prevention.\"},{\"question\":\"How were the metformin targets evaluated?\",\"answer\":\"Genetic proxies were created for 11 metformin targets based on tissue-specific gene expression, HbA1c, and type 2 diabetes associations, then tested against five major cancers using drug-target Mendelian randomization.\"},{\"question\":\"Which target showed an association with cancer risk?\",\"answer\":\"PRKAG1 (AMPKγ1) showed reduced risk of colorectal cancer, while GPD1 showed no significant association.\"}]","Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes - A Drug-Target Mendelian Randomization Study | PDF",1790094059,23,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b863c29b667bc354f79f05dc0e1f588.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00381ea1dcf9d8f5b8eabd24b8d6657d.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e776dc0c14afe11a695d1c178c79e8e5.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0af1f1774a8c152f651ed99b8bae8af4.webp",980,1287]